This site is intended only for healthcare professionals resident in Egypt




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact usAsk a questionPfizer medical information



Suspect & Detect About ATTR-CM Study Design Efficacy & Safety Profile Dosing MOD/MOA Important Safety Information Abbreviated Prescribing Information
DosingVYNDAMAX™ 61mg - a single-capsule, once-daily treatment for ATTR-CM1
  •  Capsules should be swallowed whole and not crushed or cut1


A study demonstrated the bioequivalence of VYNDAMAX™ 61 mg to 80 mg of tafamidis meglumine2

VYNDAMAX™ 61 mg is bioequivalent to 80 mg of tafamidis meglumine. Tafamidis and tafamidis meglumine are not interchangeable on a per-mg basis.2

In a phase 1, open-label, randomised, 2-period, 2-sequence, crossover, multiple-dose bioequivalence study, fasted healthy individuals (n=30)
received VYNDAMAX™ (tafamidis) 61 mg once daily or tafamidis meglumine 80 mg once daily.2‡

The study compared the area under the concentration-time profiles from time 0 to time tau (AUCtau) and the maximum observed concentration (Cmax) at steady state.2

[Bioequivalence was established by the 90% confidence interval falling within the 80%-125% bioequivalence limits for tafamidis area under curve (AUC) and peak plasma concentration (Cmax).2]

Approval of VYNDAMAX™ (tafamidis) 61 mg was based on ATTR-ACT, which evaluated the pooled 20 mg and 80 mg (4 × 20 mg) doses of tafamidismeglumine. The relative bioavailability of 61 mg of VYNDAMAX™ (tafamidis) is similar to 80 mg of tafamidismeglumine at steady state.2

*Capsule shown is not actual size.
As determined by the predefined 90% confidence interval criteria of 80%-125% bioequivalence limits for tafamidis for area under curve (AUC) and peak plasma concentration (Cmax) after repeated oral daily dosing for 7 days.2

After a twice-daily loading dose on Days 1 and 2 to reduce the time to reach steady state, patients switched to a once-daily dose for Days 3 to 7.2

ATTR-CM: transthyretin amyloid cardiomyopathy; MOA: mechanism of action; MOD: mechanism of disease.

References:VYNDAMAX™ (Tafamidis) Egyptian Drug Authority leaflet approval date 26/7/2021. Revision date: June 2021.Lockwood PA, Le VH, O'Gorman MT, et al. The bioequivalence of tafamidis 61 mg free acid capsules and tafamidis meglumine 4 × 20-mg capsules in healthy volunteers. Clin Pharmacol Drug Dev. 2020;9(7):849-854.

MOH Approval No. : HF0098OA171/082022

Invalidation Date : 11/08/2024


Support & Services
Efficacy and Safety Profile Click HereLoading
MOD/MOA Click HereLoading

Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.
For Egypt Healthcare Professionals

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.
 If you select ""No"", you will be redirected to, the global Pfoizer websitee.
 I confirm that i am a healthcare professional resident in Egypt.

Yes No